Quality of life in oncology trials: A clinical guide

Seminars in Radiation Oncology

Volumn 13, Issue 3, 2003, Pages 235-247

  Movsas, Benjamin ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER; CANCER RADIOTHERAPY; CANCER RESEARCH; CANCER SURVIVAL; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; HUMAN; MEASUREMENT; OUTCOMES RESEARCH; PATIENT SATISFACTION; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE;

EID: 0043029522     PISSN: 10534296     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1053-4296(03)00029-8     Document Type: Conference Paper

References (87)

1. Fayers P, Machin D: Quality of Life Assessment, Analysis and Interpretation. West Sussex, England, John Wiley & Sons, Ltd, 2000
2. Hyland ME: Health and values: The values underlying health measurement and health resource allocation. Psych Health 12:389-403, 1997
3. Leplege A, Hunt S: The problem of quality of life in medicine. JAMA 278:47-50, 1997
4. Till J, McNeil B, Bush R: Measurements of multiple components of quality of life. Cancer Treat Symp 1:177-181, 1984
5. Slevin ML, Plant H, Lynch D, et al: Who should measure quality of life, the doctor or the patient? Br J Cancer 57:109-112, 1988
6. Beller E, Tattersall M, Lumley T, et al: Improved quality of life with megestrol acetate in patients with endocrine-insensitive advanced cancer: A randomised placebo-controlled trial. Ann of Oncol 8:277-283, 1997
7. Coates A, Gebski V, Bishop J, et al: Improving the quality of life during chemotherapy for advanced breast cancer: A comparison of intermittent and continuous treatment strategies. N Engl J Med 317:1490-1495, 1987
8. Coates A: Prognostic implications of quality of life. Cancer Treat Rev 19:53-57, 1993 (suppl A)
9. Montazeri A, Milroy R, Hole D, et al: Quality of life in lung cancer patients: As an important prognostic factor. Lung Cancer 31:233-240, 2001
10. Langendijk H, Aaronson NK, de Jong JM, et al: The prognostic impact of quality of life assessed with the EORTC QLQ-C30 in inoperable non-small cell lung carcinoma treated with radiotherapy. Radiother Oncol 55:19-25, 2000
11. Smets EM, Visser MR, Willems-Groot AF, et al: Fatigue and radiotherapy: (B) Experience in patients 9 months following treatment. Br J Cancer 78:907-912, 1998
12. Bjordal K, Kaasa S, Mastekaasa A: Quality of life in patients treated for head and neck cancer: A follow-up Study 7 to 11 years after radiotherapy. IJROBP 28:847-856, 1994
13. Bjordal K, Kaasa S: Psychological distress in head and neck cancer patients 7-11 years after curative treatment. Br J Cancer 71:592-597, 1995
14. Movsas B: Exploring the role of the radioprotector amifostine in locally advanced non-small cell lung cancer: Radiation Therapy Oncology Group trial 98-01. Semin Radiat Oncol 12:40-45, 2002
15. Burris H, Moore M, Andersen J, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 15:2403-2413, 1997
16. Leitgeb C, Pecherstorfer M., Fritz E, et al: Quality of life in chronic anemia of cancer during treatment with recombinant human erythropoietin. Cancer 73:2535-2542, 1994
17. Revicki D, Osoba D, Fairclough D, et al: Recommendations on health-related quality of life research to support labeling and promotional claim claims in the United States. Qual Life Res 9:887-900, 2000
18. Chassany O, Sagnier P, Marquis P, et al: Patient-reported outcomes: the example of health-related quality of life: A European guidance document for the improved integration of health-related quality of life assessment in the drug regulatory process. Drug Inf J 36:209-238, 2002
19. Johnson J, Temple R: Food & Drug Administration requirements for approval of new anti-cancer drugs. Cancer Treat Rep 69:1155-1157, 1985
20. Strain J: The evaluation of quality-of-life in cancer therapy. Oncology 4:22-26, 1990
21. Cella DF, Tulsky DS: Measuring quality of life today: Methodological aspects. Oncology (Huntingt) 4:29-38; discussion 69, 1990
22. Detmar SB, Aaronson NK, Wever LD, et al: How are you feeling? Who wants to know? Patients' and oncologists' preferences for discussing health-related quality-of-life issues. J Clin Oncol 18:3295-3301, 2000
23. Slevin M, Stubbs L, Plant H, et al: Attitudes to chemotherapy: Comparing views of patients with cancer with those of doctors, nurses, and general public. Br Med J 300:1458-1460, 1990
24. Bezjak A, Taylor KM, Ng P, et al: Quality-of-life information and clinical practice: The oncologist's perspective. Cancer Prev Control 2:230-235, 1998
25. Laliberte N, Cella D, Masters G, et al: Real-time clinical application of quality of life (QOL) assessment in lung cancer: A feasibility pilot. Qual Life Res 9:293-295, 2000
26. Osoba D: The Quality of Life Committee of the Clinical Trials Group of the National Cancer Institute of Canada: Organization and functions. Qual Life Res 1:211-218, 1992
27. Aaronson N: Quality of Life and clinical trials. Lancet 346:1-2, 1995
28. Gotay C, Moore T: Assessing quality of life in head and neck cancer. Quality of Life Res 1:5-17, 1992
29. Gelber R, Gelber S: Quality of Life Assessment in Clinical Trials: Recent Advances in Clinical Trial Design and Analysis. Boston MA, Kluwer Academic Publishers. 1995
30. Ware J: Standards for validating health measures: Definition and content. J Chronic Diseases 40:473-474, 1987
31. Husted JA, Cook RJ, Farewell VT, et al: Methods for assessing responsiveness: A critical review and recommendations. J Clin Epidemiol 53:459-468, 2000
32. Roila F, Cortesi E: Quality of life as a primary end point in oncology. Ann Oncol 12:S3-S6, 2001
33. Von Neumann J, Morgenstern O: Theory of Games and Economic Behavior. Princeton NI, Princeton University Press, 1944
34. Joyce C, O'Boyle C, McGee H: Individual Quality of Life: Approaches to Conceptualisation and Assessment. Amsterdam the Netherlands, Harwood Academic Publishers, 1999
35. Testa MA, Simonson DC: Assesment of quality-of-life outcomes. N Engl J Med 334:835-840, 1996
36. Aaronson NK, Ahmedzai S, Bergman B, et al: The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365-376, 1993
37. Cella D, Tulsky D, Gray, G, et al: The functional assessment of Cancer Therapy Scale: Development and validation of the general measure. J Clin Oncol 11:570-579, 1993
38. Fayers P, Weeden S, Curran D: EORTC QLQ-C30 reference values. Brussels, 1998, p 157
39. Hjermstad M, Fayers P, Bjordal K, et al: Health-related quality of life in the general Norwegian population assessed by the EORTC core Quality of Life Questionnaire - The QLQ-C30 (+3). J Clin Oncol 16:1188-1196, 1998
40. de Haes, J, van Knippenberg F, Neijt J: Measuring psychological and physical distress in cancer patients: Structure and application of the Rotterdam Symptom Checklist. Br J Cancer 62:1034-1038, 1990
41. McCorkle R, Young K: Development of a symptom distress scale. Cancer Nurs 1:373-378, 1978
42. Schipper H, Clinch J, McMurray A, et al: Measuring the quality of life of cancer patients: The Functional Living Index-Cancer: Development and validation. J Clin Oncol 2:472-483, 1984
43. Schag CA, Ganz PA, Heinrich RL: Cancer Rehabilitation Evaluation System-short form (CARES-SF): A cancer specific rehabilitation and quality of life instrument. Cancer 68:1406-1413, 1991
44. Padilla GV, Presant C, Grant MM, et al: Quality of life index for patients with cancer. Res Nurs Health 6:117-126, 1983
45. Mosconi P, Colozza M, De Laurentiis M, et al: Survival, quality of life and breast cancer. Ann Oncol 12:S15-19, 2001 (suppl 3)
46. Gridelli C, Perrone F, Nelli F, et al: Quality of life in lung cancer patients. Ann Oncol 12:S21-25, 2001 (suppl 3)
47. Barbarisi A, Parisi V, Parmeggiani U, et al: Impact of surgical treatment on quality of life of patients with gastrointestinal tumors. Ann Oncol 12:S27-30, 2001 (suppl 3)
48. Cascinu S, Labianca R, Daniele B, et al: Survival and quality of life in gastrointestinal tumors: Two different end points? Ann Oncol 12:S31-36, 2001 (suppl 3)
49. Pignata S, Ballatori E, Favalli G, et al: Quality of life: Gynaecological cancers. Ann Oncol 12:S37-42, 2001 (suppl 3)
50. Bertetto O, Bracarda S, Tamburini M, et al: Quality of life studies and genito-urinary tumors. Ann Oncol 12:S43-48, 2001 (suppl 3)
51. Ringash J, Bezjak A: A structured review of quality of life instruments for head and neck cancer patients. Head Neck 23:201-213, 2001
52. Osoba D: Rationale for the timing of health-related quality-of-life (HQL) assessments in oncological palliative therapy. Cancer Treat Rev 22:69-73, 1996
53. Bland J, Altman D: Multiple significant tests: The Bonferroni method. Br Med J 310:170-172, 1995
54. Spranger M, Moinpour C, Moynihan T, et al: Assessing meaningful change in quality of life over time: A user's guide for clinicians. Mayo Clin Proc 77:561-571, 2002
55. Deyo R, Centor R: Assessing the responsiveness of functional scales to clinical change: An analogy to diagnostic test performance. J Chronic Dis 39:897-906, 1986
56. Kazis L, Anderson J, Meenan R: Effect sizes for interpreting changes in health status. Med Care 27:S178-S189, 1989
57. Guyatt G, Kirshner B, Jaeschke R: Measuring health status: What are the necessary measurement properties? J Clin Epidemiol 45:1341-1345, 1992
58. Wyrwich K, Tierney W, Wolinsky F: Further evidence supporting an SEM-based criterion for identifying meaningful intra-individual changes in health-related quality of life. J Clin Epidemiol 52:861-873, 1999
59. IGEO: The Italian Group for the Evaluation of Outcomes in Oncology: Patient compliance with quality of life questionnaires. Tumori 85:92-99, 1999
60. Italian Study Group TELCVISG: Effects of vinorelbine on quality of life of patients with advanced non-small cell lung cancer. J Natl Cancer Inst 91:166-172, 1999
61. Watkins Bruner D, Berk L, Bondy M, et al: Outcomes committee. Int J Radiat Oncol Biol Phys 51:66-74, 2001
62. Moinpour C, Sawyers Triplett J, McKnight B, et al: Challenges posed by non-random missing quality of life data in an advanced-stage colorectal cancer clinical trial. Psychooncology 9:340-354, 2000
63. Curtan D, Molenberghs G, Fayers P, et al: Aspects of incomplete quality oflife in randomised trials: II: Missing form. Stat Med 17:697-709, 1998
64. Fayers P, Curran D, Machin D: Incomplete quality of life data in randomized trials: Missing items. Stat Med 17:679-696, 1998
65. Sprangers M, Schwartz C: The challenge of response shift for quality-of-life-based clinical oncology research. Ann Oncol 10:747-749, 1999
66. O'Boyle C, McGee H, Browne J: Measuring response shift using the schedule for evaluation of individual quality of life, in Sprangers M (ed): Adaptation to Changing Health: Response Shift in Quality-of-Life Research. Washington, DC, American Psychological Association, 2000, pp 123-136
67. Feinstein A: Clinical biostatistics, XL: Stochastic significance, consistency, apposite data, and some other remedies for the intellectual pollutants of statistical vocabulary. Clin Pharmacol Ther 22:113-123, 1977
68. Salsburg D: Hypothesis versus significance testing for controlled clinical trials: A dialogue. Stat Med 9:201-211, 1990
69. Ware J, Keller S: Interpreting general health measures, in Spilker B (ed). Quality of life and pharmacoeconomics in clinical trials. Philadelphia PA, Lippincott-Raven, 1996, 445-460
70. Guyatt G, Osoba D, Wu A, et al: Methods to explain the clinical significance of health status measures. Mayo Clin Proc 77:371-383, 2002
71. Osoba D, Rodrigues G, Myles J, et al: Interpreting the significance of changes in health-related quality of life scores. J Clin Oncol 16:139-144, 1998
72. Santanello N, Zhang J, Seidenberg B, et al: What are minimal important changes for asthma measures in a clinical trial? Eur Respir J 14:23-27, 1999
73. King M: The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30. Qual Life Res 5:555-567, 1996
74. Osoba D, Brada M, Yung W, et al: Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme. J Clin Oncol 18:1481-1491, 2000
75. Osoba D, Tannock I, Ernst D, et al: Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone of mitoxantrone and prednisone. J Clin Oncol 17:1654-1663, 1999
76. Osoba D, Levin V, Yung W, et al: Health-related quality-of-life (HRQL) benefits in patients with recurrent anaplastic astrocytoma (AA) treated with temozolomide (TEM). Proc Am Soc Clin Oncol 17:3889, 1998
77. Cohen J: Analysis for the Behavioral Sciences (ed 2). Hillsdale, NJ, Lawrence Erlbaum Associates, 1988
78. Wyrwich K, Nienaber N, Tierney W, et al: Linking clinical relevance and statistical significance in evaluating intra-individual changes in health-related quality of life. Med Care 37:469-478, 1999
79. Frost MH, Bonomi AE, Ferrans CE, et al: Patient, clinician, and population perspectives on determining the clinical significance of quality-of-life scores. Mayo Clin Proc 77:488-494, 2002
80. Osoba D: Clinical meaningfulness (CM) of differences in health-related quality-of-life scores in clinical trials. Qual Life Res 9:256-259, 2000
81. Watkins Bruner D, Movsas B, Konski A, et al. Outcomes research in Cancer Clinical Trial Cooperative Groups: The RTOG model. J Qual Life Res (in press)
82. Movsas B, Scott C, Sause W, et al: The benefit of treatment intensification is age and histology-dependent in patients with locally advanced non-small cell lung cancer (NSCLC): A quality-adjusted survival analysis of radiation therapy oncology group (RTOG) chemoradiation studies. Int J Radiat Oncol Biol Phys 45:1143-1149, 1999
83. Movsas B, Scott C, Sause W, et al: A quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of the Radiation Therapy Oncology Group (RTOG) chemoradiation studies for locally advanced non-small cell lung cancer (LA-NSCLC). Int J Radiat Oncol Biol Phys 2002
84. Konski A, Scott C, Movsas B, et al: Cost-utility analysis of various treatments for non-small cell carcinoma of the lung. Eur J Cancer 36:S19, 2000
85. Movsas B, Scott C, Curran W, et al: A quality-adjusted time without symptoms or toxicity (QTwIST) analysis of Radiation Therapy Oncology Group (RTOG) 94-10. Proc Am Soc Clin Oncol 20:313a, 2001
86. Komaki R, Lee J, Kaplan B, et al: Randomized phase III study of chemoradiation ± amifostine in patients with inoperable stage II-III non-small cell lung cancer (NSCLC). Proc ASCO 20:325a, 2001
87. Langer C, Hsu C, Curran W, et al: Do elderly patients with locally advanced non-small cell lung cancer benefit from combined modality therapy? A secondary analysis of RTOG 9410. IJROBP 51:20, 2001